Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | RAB7A | P51149 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21253132 | 0.89 | RAB9A (0.58) | NOD1FLT3MAPTRAB7AMEN1 | |
| SCHEMBL21247278 | 0.85 | MAPT (0.67) | TNFNOD1FLT3MAPTTHRB | |
| SCHEMBL21247261 | 0.84 | GLO1 (0.50) | TNFNOD1FLT3MAPTRAB7A | |
| SCHEMBL21261089 | 0.83 | GLO1 (0.49) | TNFNOD1FLT3MAPTMEN1 | |
| SCHEMBL21247405 | 0.82 | RAB9A (0.62) | TNFNOD1FLT3MAPTMEN1 | |
| SCHEMBL21247146 | 0.82 | LMNA (0.47) | TNFNOD1MAPTMEN1KMT2A | |
| SCHEMBL21247202 | 0.82 | TNF (0.68) | TNFNOD1FLT3MAPTTHRB | |
| SCHEMBL21247321 | 0.81 | NOD1 (0.62) | TNFNOD1FLT3MAPTMEN1 | |
| SCHEMBL21250159 | 0.81 | CNR2 (0.52) | TNFNOD1MAPTRAB7AMEN1 | |
| SCHEMBL21260935 | 0.76 | CNR2 (0.43) | RAB7ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492347-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2022-11-08 | — | — | US | disclosed |
| EP-3749659-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| CN-111954668-A | Fused thiophene derivative and use thereof | 埃尼奥制药公司 | 2020-11-17 | — | — | CN | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | TNF 1354/4885NOD1 410/4885FLT3 1514/4885 |
| US-11492347-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | TNF 1354/4885NOD1 410/4885FLT3 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.